Cynapsus Therapeutics Inc (CYNA) : Havens Advisors added new position in Cynapsus Therapeutics Inc during the most recent quarter end. The investment management firm now holds 47,500 shares of Cynapsus Therapeutics Inc which is valued at $1,921,375 , the company said in a statement filed on Oct 13, 2016 with the SEC.Cynapsus Therapeutics Inc makes up approximately 1.54% of Havens Advisors’s portfolio.
Other Hedge Funds, Including , Creative Planning sold out all of its stake in CYNA during the most recent quarter. The investment firm sold 262 shares of CYNA which is valued $10,585.
Cynapsus Therapeutics Inc closed down -0.0099 points or -0.02% at $40.4001 with 53,926 shares getting traded on Tuesday. Post opening the session at $40.42, the shares hit an intraday low of $40.39 and an intraday high of $40.42 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.
Cynapsus Therapeutics Inc. is a Canada-based clinical-stage specialty pharmaceutical company. The Company is engaged in developing a sublingual thin filmstrip to manage OFF episodes associated with Parkinsons disease. The Company’s drug candidate is APL-130277 which is a reformulation of apomorphine. The drug is an approved acute drug in the United States Europe Japan and other countries. The Company completed a CTH-105 Phase II clinical trial comprising approximately 16 people with Parkinson’s disease.